CLINICAL TRIALS PROFILE FOR OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

All Clinical Trials for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	Northwestern University		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗	Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus	Completed	National Center for Research Resources (NCRR)		1995-12-01	OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00107874 ↗	Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section	Completed	Basel Women’s University Hospital	Phase 2	1999-01-01	Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00107874 ↗	Oral Misoprostol Versus Intravenous Oxytocin in Preventing Blood Loss After Non-scheduled Cesarean Section	Completed	University Hospital, Basel, Switzerland	Phase 2	1999-01-01	Postpartum hemorrhage (PPH) ranks among the leading causes of maternal morbidity and mortality, both in developed and developing countries. With this trial, we sought to determine the effectiveness of oral misoprostol as an uterotonic drug in comparison with intravenous oxytocin, in patients with a low risk of PPH undergoing non-scheduled Cesarean section. We therefore compared the intra- and postoperative blood loss, as well as drug related side effects in patients, treated by the same surgical and anesthesiological team in one institution.
NCT00114439 ↗	Lithium Cannabis Withdrawal Study	Completed	The University of New South Wales	Phase 2	2005-09-01	This trial will examine the efficacy of lithium in providing symptomatic relief from the withdrawal discomfort experienced by some dependent users of cannabis on cessation of regular use. Significant withdrawal may be a barrier to achieving abstinence in some clients and can be associated with marked disturbances in mood, sleep, hostility and aggression. Relief from such symptoms may be important in helping some clients achieve a period of abstinence and facilitate subsequent entry into a relapse prevention program.

Clinical Trial Conditions for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

Condition Name

Condition Name for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Intervention	Trials
Postpartum Hemorrhage	91
Healthy	60
Schizophrenia	30
Post Partum Hemorrhage	23

Condition MeSH

Condition MeSH for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Intervention	Trials
Hemorrhage	162
Postpartum Hemorrhage	156
Disease	37
Schizophrenia	33

Clinical Trial Locations for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

Trials by Country

Trials by Country for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Location	Trials
United States	379
Egypt	100
Canada	69
China	57
France	34

Trials by US State

Trials by US State for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Location	Trials
California	62
North Carolina	37
New York	31
Massachusetts	30
South Carolina	20

Clinical Trial Progress for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

Clinical Trial Phase

Clinical Trial Phase for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Clinical Trial Phase	Trials
PHASE4	9
PHASE3	5
PHASE2	19

Clinical Trial Status

Clinical Trial Status for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Clinical Trial Phase	Trials
Completed	410
Recruiting	152
Unknown status	97

Clinical Trial Sponsors for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%

Sponsor Name

Sponsor Name for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Sponsor	Trials
University of Electronic Science and Technology of China	46
Samuel Lunenfeld Research Institute, Mount Sinai Hospital	34
Cairo University	33

Sponsor Type

Sponsor Type for OXYTOCIN 20 USP UNITS IN DEXTROSE 5%
Sponsor	Trials
Other	1088
Industry	55
NIH	43

Last updated: April 23, 2026

Oxytocin 20 USP Units in Dextrose 5%: Clinical-Dev Update, Market Read, and Demand Projection

What is the product and how is it positioned clinically?

“Oxytocin 20 USP units in Dextrose 5%” is an oxytocin injection formulated in D5W (5% dextrose) for IV infusion or IV use in obstetrics. Clinically, oxytocin is a uterotonic used across labor induction and management of uterine atony and postpartum hemorrhage risk, with dosing and administration governed by label-specific protocols.

Across jurisdictions, oxytocin is a well-established, off-patent active ingredient; commercial differentiation is mainly driven by:

• Presentation (concentration, vial size, infusion bag vs vial, diluent system)
• Packaging formats for hospital use (single-unit vials vs multi-dose packs)
• Regulatory compliance and supply reliability
• Local tender pricing and formulary access

What is the current clinical-trials update for this exact formulation?

A clinical-trials update for this exact product presentation (oxytocin injection specified as “20 USP units in Dextrose 5%”) is not determinable from the available information in the prompt. The only defensible position, given the instruction constraints, is to treat the drug substance as established and focus the update on market and utilization rather than claim an “ongoing trials” pipeline for the precise formulation.

So the clinical-trials “update” is operational: oxytocin use continues under standard-of-care protocols, with the formulation’s role tied to IV delivery in hospital settings (labor units, L&D, postpartum hemorrhage protocols). Trial activity for oxytocin commonly centers on dosing strategies, routes, and comparative protocols, not novel chemistry of the same buffered/solvent presentation.

What market does the product serve and what are the demand drivers?

Oxytocin is purchased by hospitals and acute-care systems. The addressable demand is tied to:

• Birth volumes (labor induction and augmentation rates)
• Cesarean section mix (uterine tone management and postpartum protocols)
• Postpartum hemorrhage (PPH) incidence and adherence to uterotonic bundles
• Hospital formulary inclusion and procurement cycles
• Inventory turns and supply-chain reliability for IV uterotonics

This product’s explicit D5W diluent system matters because hospitals follow IV-compatible prep rules and standard order sets. A D5W-based oxytocin presentation is typically preferred where institutions use dextrose-containing lines for infusion compatibility or where the product is stocked as a ready-to-administer format.

Demand funnel

• Live births → labor inductions + labor augmentations + management of uterine atony/PPH
• Hospital standard protocols → number of oxytocin administrations
• Administration counts per case → proportional to dosing regimens and treatment durations
• Procurement channel → tender-driven purchasing and formulary depth

How is the market structured (supply, pricing, and buyer power)?

Oxytocin is commonly multi-source for multiple presentations. In practice, buyers negotiate:

• Annual contract pricing by procurement region
• Tender-based selection (low-cost stable supply plus compliant packaging)
• Substitution across oxytocin presentations when concentration and solubility are equivalent under label instructions

That structure creates a market profile with:

• High buyer power (hospital systems)
• Limited differentiation beyond formulation presentation, packaging, and availability
• Pricing pressure from generics/biosimilar-like substitution dynamics (for small-molecule injectables)

What is the competitive landscape for this presentation?

Competitive set generally includes:

• Branded and generic oxytocin injections with equivalent dosing (USP units)
• Oxytocin presentations in different diluents (saline vs dextrose) where label allows substitution
• Hospital-manufactured dilutions from oxytocin vials (where permitted), which can compete with ready-to-use D5W-packaged presentations

The competitive advantage for “20 USP units in Dextrose 5%” is operational:

• Reduced prep steps in urgent obstetric scenarios
• Standardization within pregnancy and postpartum order sets
• Logistics alignment with IV line compatibility practices

How to model market share and product demand

Without prescribing specific country-by-country prices or trial claims, the demand model for this presentation can be built on utilization and length-of-stay style drivers:

Core unit economics for hospital spend

• Units consumed per birth case (induction/augmentation, PPH protocols)
• Average units per treated episode (dose and infusion duration per protocol)
• Contract pricing per unit (tender-driven)

Share drivers

• Formulary inclusion rate within hospital networks
• Availability and delivery reliability
• Standardization in labor and postpartum order sets
• Substitutability vs vial-based dilution

Market projection: utilization-based forecast framework

A projection for “Oxytocin 20 USP Units in Dextrose 5%” is a function of:

1. Growth in live births
2. Share of births requiring induction/augmentation
3. PPH protocol penetration and uterotonic bundle adherence
4. Adoption of ready-to-use D5W presentation vs vial dilution
5. Procurement rationalization and tender cycles

Forecast approach (high-level)

• Base case: stable induction and PPH protocol rates with incremental uptake of standardized ready-to-administer products
• Downside: substitution toward alternative diluent presentations or vial dilution
• Upside: tighter standardization and increased protocol compliance in postpartum hemorrhage programs

This yields a forecast where:

• Volume grows in line with birth trends and increased guideline adherence.
• Revenue growth is constrained by tenders and generic substitution.
• Units growth can exceed value growth if pricing compresses.

Because the prompt does not include regional scope, baseline unit prices, birth forecasts, induction/PPH incidence assumptions, or existing sales volumes for the exact presentation, any numeric projection would be fabricated. The only correct projection under the constraints is a framework-based directional outlook, not a numeric forecast.

Key regulatory and lifecycle considerations (product-specific)

What is the lifecycle status likely to be?

Oxytocin is widely used and typically off-patent at the API level; therefore, lifecycle risk is mainly:

• Labeling and manufacturing compliance
• Supply disruptions
• Tender substitution across equivalent presentations
• Solvent/diluent-specific handling constraints at hospital level

What regulatory path applies to new entrants?

For this exact formulation, new entrants typically rely on:

• Generic formulation approvals or abbreviated pathways (jurisdiction-dependent)
• Demonstration of pharmaceutical equivalence and stability for the D5W system
• Packaging and shelf-life compliance for IV readiness

Investment and R&D implications

Is there a credible pipeline differentiation path?

For this presentation, differentiation is usually not chemistry-driven. Credible pathways tend to be:

• Packaging and ready-to-administer usability
• Stability and shelf-life performance that improves inventory logistics
• D5W compatibility claims aligned with hospital infusion protocols
• Supply chain reliability and tender responsiveness

What is the business risk profile?

• High procurement price sensitivity
• Repeat-buy from hospitals with tight tender cycles
• Low tolerance for supply gaps
• Limited room for premium pricing unless operational readiness is demonstrably better in institutional procurement frameworks

Key Takeaways

• Oxytocin 20 USP units in Dextrose 5% is an IV obstetric uterotonic presentation used in labor management and postpartum hemorrhage protocols.
• The clinical “trial” update for the exact formulation is not determinable from the provided information; the practical update is that standard-of-care use continues and drives routine consumption.
• Market demand is utilization-based: live births, induction/augmentation rates, PPH protocol adherence, and adoption of ready-to-administer D5W presentation.
• Market projections should be modeled on utilization growth and tender-driven pricing compression; numeric forecasts require baseline sales, region, and pricing data that are not provided.

FAQs

1. What does “20 USP units in Dextrose 5%” mean for administration?
   It specifies oxytocin strength measured in USP units, packaged in a D5W diluent system for IV use.

2. Where is this product used in hospitals?
   Primarily in labor and delivery units and postpartum/PPH management pathways.

3. What drives hospital purchasing decisions for oxytocin IV products?
   Formulary inclusion, tender price, supply reliability, and compatibility with standard infusion workflows.

4. Does oxytocin have an active patent-protected pipeline for this presentation?
   The oxytocin molecule is widely established; differentiation is usually not patent-driven at the molecule level, and instead comes from formulation, packaging, and supply.

5. How should a market forecast for this product be built?
   Use birth and obstetric protocol utilization as the demand engine, then apply adoption of the D5W ready-to-administer format and adjust for procurement price compression.

References

[1] FDA. Oxytocin labeling and prescribing information database. (Accessed via FDA Drugs@FDA).
[2] EMA. Public assessment reports and product information for oxytocin-containing medicines. (Accessed via EMA).
[3] WHO. Recommendations on uterotonics for the prevention and treatment of postpartum hemorrhage. WHO guidance documents.